335 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22632 | any line, RECIST 1.1 | Philippe Aftimos | Multiple | Amcure GmbH | AMC303-01 | Trial closed | A safety, tolerability and pharmacokinetic dose escalation expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin | philippe.aftimos@hubruxelles.be | 1/1b | 1 | |
| 22966 | Nathalie Meuleman | Amgen | AMG420 -20160370 | Trial closed for recruitment | A Phase 1b/2 Multicenter, Open-label, Expansion Study to Assess the Safety and Efficacy of AMG 420 as Monotherapy in Subjects With Relapsed and/or Refractory Multiple Myeloma | nathalie.meuleman@hubruxelles.be | 1/2 | 1 | |||
| 22732 | Locally-advanced or metastatic malignancy with : KRAS p.G12Cmutation | Nuria Kotecki | Multiple | Amgen | AMG510 | Trial closed for recruitment | A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation | Nuria.Kotecki@hubruxelles.be | 1/2 | 1 | |
| 22718 | Ongoing problemn with apetite/eating. Maximum 3 lines of systemic prior | Thierry Berghmans | NSCLC | Helsinn Healthcare SA | ANAM-17-21 | Trial closed | A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Anamorelin HCL for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced nonsmall cell lung cancer (NSCLC) | 3 | 3 | ||
| 22634 | - Histopathological diagnosis of amyloidosis - Measurable disease of amyloid light chain amyloidosis as defined by at least ONE of the following: serum M-protein ?0.5 g/dL by protein electrophoresis or serum free light chain ?50 mg/L - One or more organs |
Nathalie Meuleman | Amyloidose | Janssen | ANDROMEDA | Trial closed for recruitment | A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis | nathalie.meuleman@hubruxelles.be | 3 | 3 | |
| 22775 | second line metastatic | Thierry Gil | Multiple | EORTC | ANITA | Trial closed | A phase II multicenter study comparing the efficacy of the oral angiogenesis inhibitor nintedanib with the intravenous cytotoxic compound ifosfamide for treatment of patients with advanced metastatic soft tissue sarcoma after failure of systemic non-oxazaphosphorine-based first line chemotherapy for inoperable disease | thierry.gil@hubruxelles.be | 2 | 2 | |
| 22814 | Non metastatic, operable HER2+ carcinoma of the breast | Martine Piccart | Breast | Roche | APHINITY | Trial closed for recruitment | A randomised multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer. | martine.piccart@hubruxelles.be | |||
| 22704 | Stage II or stage III, early invasive breast cancer. ER+/HER2- | Michail Ignatiadis | Breast | EORTC | APPALACHES | Trial closed for recruitment | A Phase II study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS with high-risk ER+/HER2- early breast cancer (APPALACHES) (PILOT039) | michail.ignatiadis@hubruxelles.be | 2 | 2 | |
| 22652 | EGFR activating mutation associated with EGFR-TKI sensitivity | Thierry Berghmans | Lung | EORTC | Apple | Trial closed | APPLE trial: Feasibility and activity of AZD9291 (osimertinib) treatment on Positive PLasma T790M in EGFR mutant NSCLC patients | 3 | 3 | ||
| 22771 | Metastatic | Spyridon Sideris | prostate | Bayer | ARASENS | Trial closed | A randomized, double blind, placebo controlled Phase III study of ODM 201 versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone sensitive prostate cancer | spyridon.sideris@hubruxelles.be | 3 | 3 | |
| 29048 | Mariana Brandao | Lung | AstraZeneca | ARTEMIDE-01 | Trial open for recruitment | A Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD2936 Anti TIGIT/Anti-PD-1 Bispecific Antibody in Participants with Advanced or Metastatic Non small Cell Lung Cancer (ARTEMIDE-01)(D7020C00001) | mariana.brandao@hubruxelles.be | 1/2 | 1 | ||
| 22661 | 3rd line metastatic | Philippe Aftimos | Breast | Immunomedics | Ascent | Trial closed | An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments | philippe.aftimos@hubruxelles.be | 3 | 3 | |
| 29591 | Evandro De Azambuja | Breast | Gilead Science | ASCENT-04 | Trial open for recruitment | A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1 | 3 | 3 | |||
| 28653 | age >= 18 YO CTCL-PTCL >= 3th line |
Marie Maerevoet | Lymphoma | Astex Pharmaceuticals | ASTX660-01 | Trial closed | Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas | marie.maerevoet@hubruxelles.be | 1/2 | 1 |